Futura Medical PLC Total Voting Rights
October 01 2024 - 2:00AM
RNS Regulatory News
RNS Number : 3138G
Futura Medical PLC
01 October 2024
1 October 2024
Futura
Medical plc
("Futura", "the Group" or the "Company")
Total
Voting Rights
Futura Medical plc (AIM: FUM),
the pharmaceutical company developing innovative sexual health
products, announces that for the purposes of the FCA's Disclosure
and Transparency Rules, the Company's total issued share capital at
the date of this announcement is 302,403,003 Ordinary
Shares.
Since the Company currently holds no
shares in treasury, the total number of voting rights in the
Company is 302,403,003 and this figure may therefore be used by
shareholders as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change in their interest in, the share capital of the Company
under the FCA's Disclosure and Transparency Rules.
Contacts:
Futura Medical plc
|
James Barder
Chief Executive Officer
Angela Hildreth
Finance Director and COO
|
investor.relations@futuramedical.com
+44 (0)1483 685 670
www.futuramedical.com
|
Panmure Liberum
Nominated Adviser
and Broker
|
Emma Earl,
Will Goode, Mark Rogers (Corporate Finance)
Rupert Dearden (Corporate
Broking)
|
+44 (0)20 3100 2000
|
|
|
|
Stifel Nicolaus Europe Limited
Joint Broker
|
Alan Selby
Ben Maddison
|
+44 (0)207 710 7600
|
|
|
|
Alma
Strategic Communications
|
Rebecca Sanders-Hewett
Sam Modlin
Will Ellis Hancock
|
+44 (0)20 3405 0205
futura@almastrategic.com
|
|
|
|
Notes to Editors:
Futura Medical plc (AIM: FUM) is the
developer of innovative sexual health products, including lead
product Eroxon. Our core strength lies in our research, development
and commercialisation of topically delivered gel formulations in
sexual health products.
Eroxon, Futura's clinically proven
lead product, has been developed for the treatment of Erectile
Dysfunction ("ED"). The highly differentiated product,
which is the only topical gel treatment for ED available over the
counter and helps men get an erection in ten
minutes, addresses significant unmet needs in the ED
market.
ED impacts 1 in 5 men globally across
all adult age brackets, with approximately half of all men over 40
experiencing ED and 25% of all new diagnoses being in men under
40.
Futura has distribution partners in
place in a number of major consumer markets including Haleon in the
US, the largest market for ED in the world, and Cooper Consumer
Health in Europe. Eroxon has been nominated for a number of
healthcare industry awards and has won two to-date.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
TVRDZGFLKGVGDZM
Futura Medical (LSE:FUM)
Historical Stock Chart
From Oct 2024 to Nov 2024
Futura Medical (LSE:FUM)
Historical Stock Chart
From Nov 2023 to Nov 2024